Selected research
Industry Research
Human Insulin Industry Research Report 2026
Market perspective
The global Human Insulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Insulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Insulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Insulin include Sanofi, ELI Lilly, B. Braun, Ypsomed, Wockhardt, NOVO Nordisk, Julphar, Biodel and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Insulin market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Insulin Market by Company
Sanofi
ELI Lilly
B. Braun
Ypsomed
Wockhardt
NOVO Nordisk
Julphar
Biodel
Biocon
Becton, Dickinson
Human Insulin Segment by Type
Insulin Analogs and Biosimilars
Human Insulin Biologics
Human Insulin Segment by Application
Short Acting
Pre-Mix Insulin
Long Acting
Intermediate Acting
Human Insulin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
Applications
- Short Acting
- Pre-Mix Insulin
- Long Acting
- Intermediate Acting
Companies covered
- Sanofi
- ELI Lilly
- B. Braun
- Ypsomed
- Wockhardt
- NOVO Nordisk
- Julphar
- Biodel
- Biocon
- Becton, Dickinson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Insulin Market Size (2021-2032)
- 2.2.2 Global Human Insulin Sales (2021-2032)
- 2.2.3 Global Human Insulin Market Average Price (2021-2032)
- 2.3 Human Insulin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Insulin Analogs and Biosimilars
- 2.3.3 Human Insulin Biologics
- 2.4 Human Insulin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Short Acting
- 2.4.3 Pre-Mix Insulin
- 2.4.4 Long Acting
- 2.4.5 Intermediate Acting
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Insulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Insulin Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Human Insulin Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Insulin Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Insulin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Insulin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Insulin, Product Type & Application
- 3.8 Global Manufacturers of Human Insulin, Established Date
- 3.9 Global Human Insulin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Human Insulin Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 ELI Lilly
- 4.2.1 ELI Lilly Company Information
- 4.2.2 ELI Lilly Business Overview
- 4.2.3 ELI Lilly Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 ELI Lilly Human Insulin Product Portfolio
- 4.2.5 ELI Lilly Recent Developments
- 4.3 B. Braun
- 4.3.1 B. Braun Company Information
- 4.3.2 B. Braun Business Overview
- 4.3.3 B. Braun Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 B. Braun Human Insulin Product Portfolio
- 4.3.5 B. Braun Recent Developments
- 4.4 Ypsomed
- 4.4.1 Ypsomed Company Information
- 4.4.2 Ypsomed Business Overview
- 4.4.3 Ypsomed Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ypsomed Human Insulin Product Portfolio
- 4.4.5 Ypsomed Recent Developments
- 4.5 Wockhardt
- 4.5.1 Wockhardt Company Information
- 4.5.2 Wockhardt Business Overview
- 4.5.3 Wockhardt Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Wockhardt Human Insulin Product Portfolio
- 4.5.5 Wockhardt Recent Developments
- 4.6 NOVO Nordisk
- 4.6.1 NOVO Nordisk Company Information
- 4.6.2 NOVO Nordisk Business Overview
- 4.6.3 NOVO Nordisk Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 NOVO Nordisk Human Insulin Product Portfolio
- 4.6.5 NOVO Nordisk Recent Developments
- 4.7 Julphar
- 4.7.1 Julphar Company Information
- 4.7.2 Julphar Business Overview
- 4.7.3 Julphar Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Julphar Human Insulin Product Portfolio
- 4.7.5 Julphar Recent Developments
- 4.8 Biodel
- 4.8.1 Biodel Company Information
- 4.8.2 Biodel Business Overview
- 4.8.3 Biodel Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biodel Human Insulin Product Portfolio
- 4.8.5 Biodel Recent Developments
- 4.9 Biocon
- 4.9.1 Biocon Company Information
- 4.9.2 Biocon Business Overview
- 4.9.3 Biocon Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biocon Human Insulin Product Portfolio
- 4.9.5 Biocon Recent Developments
- 4.10 Becton, Dickinson
- 4.10.1 Becton, Dickinson Company Information
- 4.10.2 Becton, Dickinson Business Overview
- 4.10.3 Becton, Dickinson Human Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Becton, Dickinson Human Insulin Product Portfolio
- 4.10.5 Becton, Dickinson Recent Developments
5 Global Human Insulin Market Scenario by Region
- 5.1 Global Human Insulin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Insulin Sales by Region: 2021-2032
- 5.2.1 Global Human Insulin Sales by Region: 2021-2026
- 5.2.2 Global Human Insulin Sales by Region: 2027-2032
- 5.3 Global Human Insulin Revenue by Region: 2021-2032
- 5.3.1 Global Human Insulin Revenue by Region: 2021-2026
- 5.3.2 Global Human Insulin Revenue by Region: 2027-2032
- 5.4 North America Human Insulin Market Facts & Figures by Country
- 5.4.1 North America Human Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Insulin Sales by Country (2021-2032)
- 5.4.3 North America Human Insulin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Human Insulin Market Facts & Figures by Country
- 5.5.1 Europe Human Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Insulin Sales by Country (2021-2032)
- 5.5.3 Europe Human Insulin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Human Insulin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Insulin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Insulin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Insulin Market Facts & Figures by Country
- 5.7.1 South America Human Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Insulin Sales by Country (2021-2032)
- 5.7.3 South America Human Insulin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Human Insulin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Insulin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Insulin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Human Insulin Sales by Type (2021-2032)
- 6.1.1 Global Human Insulin Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Human Insulin Sales Market Share by Type (2021-2032)
- 6.2 Global Human Insulin Revenue by Type (2021-2032)
- 6.2.1 Global Human Insulin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Insulin Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Insulin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Insulin Sales by Application (2021-2032)
- 7.1.1 Global Human Insulin Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Human Insulin Sales Market Share by Application (2021-2032)
- 7.2 Global Human Insulin Revenue by Application (2021-2032)
- 7.2.1 Global Human Insulin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Insulin Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Insulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Insulin Value Chain Analysis
- 8.1.1 Human Insulin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Insulin Production Mode & Process
- 8.2 Human Insulin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Insulin Distributors
- 8.2.3 Human Insulin Customers
9 Global Human Insulin Analyzing Market Dynamics
- 9.1 Human Insulin Industry Trends
- 9.2 Human Insulin Industry Drivers
- 9.3 Human Insulin Industry Opportunities and Challenges
- 9.4 Human Insulin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst